Viatris (VTRS)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-08
$16.96+0.95%
Close 2026-07-07 · 1-day change
Reading VTRS? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track VTRS free→NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-08
Reading VTRS? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track VTRS free→QuarterlyIQ Insights · VTRS
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. On July 1, 2026 (the “Closing Date”), Viatris Inc. (“Viatris”) entered into an amended and restated term loan credit agreement (the “Amended and Restated Term Loan Credit Agreement”), among Viatris, the guarantors from time to time party thereto, the lenders from time to time party thereto and Mizuho Bank, Ltd., as administrative agent. The Amended and Restated Term Loan Credit Agreement provides for a ¥40,000,000,000 principal amount senior unsecur…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Entry into a Material Definitive Agreement. On June 17, 2026, Viatris Inc. (“Viatris” or the “Company”) completed a public offering of €650,000,000 aggregate principal amount of its 4.250% Senior Notes due 2033 (the “Notes”). The Notes are senior unsecured obligations of Viatris. The Notes are guaranteed on a senior unsecured basis by Mylan Inc., Mylan II B.V. and Utah Acquisition Sub Inc. (the “Guarantors”). The Company intends to use the net proceeds from the offering (i) to fund the repaym…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Other Events. On June 12, 2026, Viatris Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the several underwriters named in Schedule I thereto, for whom BNP PARIBAS, Citigroup Global Markets Limited and Goldman Sachs & Co. LLC are acting as representatives, to issue and sell (the “Offering”) €650,000,000 principal amount of its 4.250% Senior Notes due 2033 (the “Notes”). The Notes are being offered pursuant to a Registration Statement on Form S-3…
Results of Operations and Financial Condition. On May 7, 2026 , Viatris Inc. (“Viatris” or the “Company”) issued a press release reporting the Company's financial results for the period ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange…
Chief Financial Officer — Theodora (“Doretta”) Mistras: Ms. Mistras voluntarily ceased to serve as Chief Financial Officer to pursue another professional opportunity.
Other Events. As previously announced, Viatris will host a conference call and live webcast today at 8:30 a.m. ET to review the Company's financial results for the fourth quarter and full year 2025. Forward-Looking Statements. This report includes statements that constitute “forward-looking statements” regarding the expected financial performance of Viatris and its strategic and operational plans, including statements regarding Viatris initiated an EWSR to enable the Company to build a more f…
Costs Associated with Exit or Disposal Activities. In 2025, Viatris initiated an enterprise-wide strategic review (“EWSR”) to enable the Company to build a more focused, efficient and future-ready organization and position the Company for sustained growth beginning in 2026. On February 26, 2026, the Company announced the results of its EWSR, and as a part of the review, committed to and began implementation of certain restructuring activities. These restructuring activities are expected to op…
Results of Operations and Financial Condition. On February 26, 2026, Viatris Inc. (“Viatris” or the “Company”) issued a press release reporting the Company's financial results for the period ended December 31, 2025 and announcing 2026 guidance. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange A…
Chief Legal Officer — Brian Roman: Brian Roman is departing from his role as Chief Legal Officer, and a new executive will take over.
Director and Committee Member — David Simmons: Mr. Simmons was appointed to serve on the Compensation Committee and the Science and Technology Committee.
Results of Operations and Financial Condition. On November 6, 2025 , Viatris Inc. (“Viatris” or the “Company”) issued a press release reporting the Company's financial results for the period ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the…
Results of Operations and Financial Condition. On August 7, 2025 , Viatris Inc. (“Viatris” or the “Company”) issued a press release reporting the Company's financial results for the period ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan…
Director — David Simmons: The company appointed David Simmons as an independent director.
Results of Operations and Financial Condition. On May 8, 2025 , Viatris Inc. (“Viatris” or the “Company”) issued a press release reporting the Company's financial results for the period ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange…
Director — Rajiv Malik and Harry Korman: Two directors are retiring, but two new independent directors were appointed.
Results of Operations and Financial Condition. On February 27, 2025, Viatris Inc. (“Viatris” or the “Company”) issued a press release reporting the Company's financial results for the period ended December 31, 2024 and announcing 2025 guidance. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange A…
Results of Operations and Financial Condition. On November 7, 2024 , Viatris Inc. (“Viatris” or the “Company”) issued a press release reporting the Company's financial results for the period ended September 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the…
Entry into a Material Definitive Agreement. On September 27, 2024, Viatris Inc. (“Viatris”) entered into the Second Amended and Restated Revolving Credit Agreement (as defined and described below). Second Amended and Restated Revolving Credit Agreement On September 27, 2024, Viatris entered into an amended and restated revolving credit agreement (the “Second Amended and Restated Revolving Credit Agreement”), by and among Viatris, certain affiliates and subsidiaries of Viatris as guarantors, c…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Regulation FD Disclosure. On September 4, 2024, Viatris Inc. (the “Company”) issued a press release (the “Tender Offer Press Release”) announcing that it and its subsidiaries Mylan Inc. (“Mylan”) and Utah Acquisition Sub Inc. (“Utah Acquisition”) have commenced offers to purchase for cash (the “Tender Offers”) (i) any and all of the outstanding 1.650% Senior Notes due 2025 issued by the Company (the “Viatris Notes”), (ii) any and all of the outstanding 2.125% Senior Notes due 2025 issued by M…
Results of Operations and Financial Condition. On August 8, 2024 , Viatris Inc. (“Viatris” or the “Company”) issued a press release reporting the Company's financial results for the period ended June 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan…
Completion of Acquisition or Disposition of Assets. On July 3, 2024, Viatris Inc., a Delaware corporation (“ Viatris ” or the “ Company ”), closed the previously announced transaction with Cooper Consumer Health SAS, a French corporation (“ Cooper Consumer Health ”), involving the divestiture by Viatris of substantially all of Viatris’ over-the-counter products business (the “ Business ”) and related assets and liabilities (the “ Transaction ”), to Cooper Consumer Health and certain of its af…
Director — Rogério Vivaldi Coelho, M.D., M.B.A.: The company appointed a new independent director to the Board and assigned him to the Science and Technology Committee.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.